Hospital Acquired Infection Control Market to Hit USD 41.6B by 2033, Driven by AMR Burden and Regulatory Pressure

London, 2025 — Claritas Intelligence has published its latest global market report on the hospital acquired infection (HAI) control sector. The base case estimates the market at USD 25.3 billion in 2025, projecting growth to USD 41.6 billion by 2033, a 6.4% CAGR over the 2025–2033 forecast window.

Antimicrobial resistance is the primary structural demand engine. A 1,662-citation peer-reviewed analysis now frames AMR as a serious and growing global public-health threat, a designation that compels hospital formulary committees to adopt higher-cost second- and third-line anti-infectives across ESBL, carbapenem-resistant organism, and azole-resistant fungal phenotypes. That formulary pressure is compounded in the United States by the CMS Hospital-Acquired Condition Reduction Program, which cuts Medicare payments by 1% for institutions in the lowest-performing quartile on HAI quality metrics. The penalty mechanism effectively converts HAI control spending from discretionary capital to an obligatory line item for most U.S. acute-care institutions. Surgical volume growth adds a further, near-linear demand signal: each procedure triggers SSI prophylaxis protocols, and an active Phase 3 study of piperacillin-tazobactam prophylaxis post-pancreaticoduodenectomy (NCT06123169) represents a label-expansion opportunity the report estimates at a USD 1.8 billion TAM by 2028 (Claritas model).

North America holds an estimated 38% market share, anchored by U.S. per-capita health expenditure of USD 13,473 in 2023, the highest of any geography included in the model. The report cross-validates the base-year estimate against Ecolab's FY2025 total revenue of USD 16.08 billion and Cardinal Health's supply-chain throughput of USD 222.58 billion, both of which route material volumes of antimicrobial and sterilization products to acute-care institutions. Asia Pacific is the fastest-growing region: while China's health spend per capita stood at USD 763 in 2023, accelerating hospital infrastructure buildout is pulling AMR drug adoption curves forward at rates that outpace more mature geographies. Global health expenditure reached 10.02% of GDP and USD 1,317 per capita in 2023, expanding the aggregate procurement budget available to middle-income country health systems transitioning toward branded and novel anti-infective products.

The report also flags a scenario most incumbent vendor models have not fully priced. An active trial in Metz-Thionville (NCT05475574) is testing discontinuation of contact precautions for ESBL-colonized patients in geriatric units. A positive readout could reduce disposable PPE utilization and shrink the surface-disinfection consumables segment in elderly-care settings by an estimated 8–12% within that channel (Claritas model). Separately, azole-resistant Aspergillus propagation through agricultural-clinical cross-contamination pathways threatens to render existing antifungal prophylaxis protocols obsolete before replacement pipeline candidates, such as those under evaluation in NCT06532227, can clear regulatory hurdles. Legacy sterilization incumbents, including Getinge AB (founded 1904) and Heraeus (founded 1851, 16,200 employees), face additional margin compression from generic antimicrobial formulations entering biosimilar-adjacent competitive dynamics.

"The AMR demand premium is real and durable, but the market's risk distribution is uneven. Formulary expansion for high-cost anti-infectives benefits pharma names like Pfizer, Merck, Gilead, and Astellas disproportionately, while consumables vendors face a credible volume headwind if contact-precaution discontinuation trials read out positively. Investors and strategy teams should model both scenarios rather than anchoring to the consensus growth story alone." — Ananya Sharma, Claritas Intelligence

The report segments the market by therapeutic area, drug class and mechanism of action, route of administration, indication, end-user care setting, and payer type. Companies profiled include 3M Company, Ecolab Inc., Cardinal Health Inc., Getinge AB, Heraeus Holding GmbH, Cantel Medical Corp. (a Steris company), Steris plc, Becton Dickinson and Company, Pfizer Inc., Merck & Co. Inc., Gilead Sciences Inc., and Astellas Pharma Inc.

About Claritas Intelligence: Claritas Intelligence is a global market intelligence publisher providing rigorous quantitative forecasts, competitive landscaping, and strategic analysis across life sciences, industrials, and technology sectors. Our research is used by investment teams, corporate strategy functions, and policy advisors across more than 60 countries.

The full analysis, including segmentation, regional breakdowns, forecasts, and company profiles, is available in the Hospital Acquired Infection Control Market Report.